




PHARMACEUTICAL 2023

CONTRAFECT Corp
Rank 413 of 446





PHARMACEUTICAL 2023

CONTRAFECT Corp Rank 413 of 446

The relative strengths and weaknesses of CONTRAFECT Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CONTRAFECT Corp compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 6.8% points. The greatest weakness of CONTRAFECT Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 192% points.

The company's Economic Capital Ratio, given in the ranking table, is -321%, being 365% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	17,706
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,840
Liabilities, Non-Current	2,392
Other Assets	2,346
Other Compr. Net Income	52
Other Expenses	7,719
Other Liabilities	9,299
Other Net Income	-545
Other Revenues	0
Property and Equipment	627
Research and Development	44,738
Selling, General and Administrative Expense	12,151

Output Variable	Value in 1000 USD
Assets	20,679
Liabilities	32,531
Expenses	64,608
Revenues	0
Stockholders Equity	-11,852
Net Income	-65,153
Comprehensive Net Income	-65,127
Economic Capital Ratio	-321%